Inventurus Knowledge Solutions Limited has informed the Exchange regarding a press release dated May 13, 2026, titled "Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026.".
IKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
IKS Health reported exceptional FY26 results with 20% YoY revenue growth to ₹31,938 million and a 48% surge in PAT to ₹7,216 million. EBITDA grew 38% to ₹10,913 million, while Adjusted PAT rose 47% to ₹8,087 million. Q4 FY26 also showed strong performance with 18.5% revenue growth and 39.4% PAT growth. The company credited its AI+Human care enablement model and expanded partnerships with major US health systems for the growth. The CFO specifically highlighted significant margin expansion and operational discipline as key drivers.
Strong operational execution with margin expansion demonstrates the company's ability to scale profitably. The 48% PAT growth significantly outpacing 20% revenue growth signals improving profitability and efficiency, which could be positive for the stock given the company listed just over a year ago.